Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Upper limbs in adults
- Lower limbs in adults affecting the ankle joint
Please click here to see the full therapeutic indications.
Adult Spasticity
Making sense of the changing NHS and funding flows
12 minutes
Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.
DYS-UK-007356
Navigating the Switch between BoNT-As: The North Staffordshire Rehabilitation Centre Experience
10 minutes
Dr Clive Bezzina shares his personal experience switching between BoNT-As within his spasticity service, and the outcomes seen for both the patients and the service.
DYS-UK-007573
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. February 2024 DYS-UK-008398
